Patrick Cox has lived deep inside transformative technologies for over 25 years. In the 1980s, he worked in software development and manufacturing. By the mid-‘90s, he consulted for Netscape–which handled 90% of all Internet browsing traffic at the time. InfoWorld and USA Today have featured his research, and he’s written for The Wall Street Journal, Los Angeles Times, USA Today and Reason Magazine. Patrick has appeared on Crossfire and Nightline, and been written up in The Baltimore Sun and CNBC Magazine. Now, Patrick edits Breakthrough Technology Alert and Technology Profits Confidential, uncovering transformational technologies that offer exponential gains.
Today we're introducing you to a longtime colleague, Patrick Cox. Patrick's spent a decade researching the subject of life-extension. And we're convinced he may have uncovered the precursor to a true "fountain of youth." This could be the most groundbreaking news of our lifetime.
Innovate or DiePresentation: Shorting the Apocalypse: Two video presentations, nearly two hours in combined length, filmed at Agora Financial’s $1,000-per-ticket annual Vancouver investment symposium.
As this is my last regularly scheduled weekly for Agora Financial, I'd like to thank those who have sent me personal messages. I'd also like to thank the crew who made my term with the company possible and pleasant, including Addison Wiggin, Chris Mayer and Joe Schriefer, as well as my editor Jessica Comitto and colleague Ray Blanco. Also, of course, thank you.
Unless you're new here, you know about priority review vouchers (PRV). Designed by Duke University economists as a means of encouraging the development of drugs for unaddressed tropical diseases, PRVs were made law in 2007. Essentially, they are transferable go-to-the-front-of-the-regulatory-line “chits” awarded to companies that develop approved drugs for these orphan diseases. Estimates of the financial value of these chits range from $200 million to well over a half billion.
After writing this week's alert about the benefit to BioTime from the Supreme Court gene ruling, another story broke with profound implications for the company. You may, in fact, have seen one of the many stories written about the University of Rochester discovery regarding the extremely long life spans of Heterocephalus glaber, aka the naked mole rat. Dozens of publications carried the story involving this unlikely creature.
Whenever the Supreme Court hands down a ruling on some company's patent claim to a gene, markets tend to react, as investors worry about possibly far-reaching consequences. This isn't, of course, surprising. The science behind gene patents is complicated. Biotech patent law is just as confusing, but is even more inscrutable because it is decided by humans, rather than nature. At stake are thousands of gene patents.
The tropical storm in the Gulf of Mexico that was sending daily storms over south Florida has passed. Though I usually don't run on days when I'm writing these weekly communiques, I felt compelled to head for the beach in my new Merrell Barefoot Vapor Gloves. These barefoot or minimalist running shoes are considered new technology, but they look almost exactly like the shoes my father used when he was running in the 1930s.
Last week, I wrote extensively about the impact of anatabine citrate, the active ingredient in Star Scientific's Anatabloc, on my glaucoma. I may be, in fact, the first person ever to experience a significant reversal of glaucoma, so it is relevant to investors. I admit, however, that I droned on about the difficulties I've experienced adapting to the restoration of binocular vision.
Periodically, I forget that the rate of scientific change is accelerating exponentially. If you're paying attention to the people who are actually pushing the scientific envelope, you will be astonished by the progress and the wealth it is creating. It is, however, easy to be lulled into complacency. This is especially true during dramatic events, such as the current meltdown of Chicago-style federal governance.